Approval for a modification of the indications for use of the system. the device, as modified, will be marketed under the trade name liposorber la-15 system and is indicated for use in performing low density lipoprotein cholesterol (ldl-c) apheresis to acutely remove ldl-c from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated: 1) group a  functional hypercholesterolemic homozygotes with ldl-c > 500 mg/dl; 2) group b  functional hypercholesterolemic heterozygotes with ldl-c >= 300 mg/dl; and 3) group c  functional hypercholesterolemic heterozygotes with ldl-c >= 160 mg/dl and documented coronary heart disease.